HRP20190181T4 - Farmaceutski dozni oblik za trenutno oslobađanje jednog derivata indolinona - Google Patents
Farmaceutski dozni oblik za trenutno oslobađanje jednog derivata indolinona Download PDFInfo
- Publication number
- HRP20190181T4 HRP20190181T4 HRP20190181TT HRP20190181T HRP20190181T4 HR P20190181 T4 HRP20190181 T4 HR P20190181T4 HR P20190181T T HRP20190181T T HR P20190181TT HR P20190181 T HRP20190181 T HR P20190181T HR P20190181 T4 HRP20190181 T4 HR P20190181T4
- Authority
- HR
- Croatia
- Prior art keywords
- dosage form
- pharmaceutical dosage
- active substance
- form according
- mass percent
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims 12
- 239000012729 immediate-release (IR) formulation Substances 0.000 title claims 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 239000013543 active substance Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 239000012458 free base Substances 0.000 claims 6
- 239000007903 gelatin capsule Substances 0.000 claims 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- 239000003925 fat Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- USSDHQBDGKZOQQ-FJBFXRHMSA-N C(C)OS(=O)=O.CN1CCN(CC1)CC(=O)N(C)C1=CC=C(C=C1)N\C(\C1=CC=CC=C1)=C\1/C(NC2=CC(=CC=C12)C(=O)OC)=O Chemical compound C(C)OS(=O)=O.CN1CCN(CC1)CC(=O)N(C)C1=CC=C(C=C1)N\C(\C1=CC=CC=C1)=C\1/C(NC2=CC(=CC=C12)C(=O)OC)=O USSDHQBDGKZOQQ-FJBFXRHMSA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000012738 dissolution medium Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Business, Economics & Management (AREA)
- Physics & Mathematics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Educational Technology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Educational Administration (AREA)
- Physical Education & Sports Medicine (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Entrepreneurship & Innovation (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Farmaceutski oblik za doziranje djelatne tvari 3-Z-[1-(4-(N-((4-metil-piperazin-1-il)-metilkarbonil)-N-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetilsulfonata, naznačen time, da on dostavlja profil trenutnog oslobađanja u kojem se ne manje od 70% (Q65%) djelatne tvari otapa u vremenu od 60 minuta in vitro pod sljedećim uvjetima in vitro otapanja u skladu s Europskom Farmakopejom 6.2: uređaj 2 (lopatice), medij za otapanje s 0,1 M HCl (pH 1) i brzina miješanja od 50 do 150 rpm, na temperaturi od 37°C, te time, da obuhvaća viskoznu lipidnu suspenzijsku formulaciju od 10 do 50 masenih postotaka djelatne tvari u 10 do 70 masenih postotaka triglicerida srednjeg lanca, 1 do 30 masenih postotaka teških masti i 0,1 do 10 masenih postotaka lecitina, na temelju ukupne mase viskozne lipidne suspenzijske formulacije.
2. Farmaceutski oblik za doziranje prema patentnom zahtjevu 1, naznačen time, da obuhvaća vrijednosti raspona za doziranje između 25 i 300 mg djelatne tvari.
3. Farmaceutski oblik za doziranje prema patentnom zahtjevu 1, naznačen time, da obuhvaća 10 do 70 masenih postotaka triglicerida srednjeg lanca, 10 do 30 masenih postotaka teških masti i 0,25 do 2,5 masenih postotaka lecitina.
4. Farmaceutski oblik za doziranje prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je oblik za doziranje prikladan za oralnu isporuku.
5. Farmaceutski oblik za doziranje prema patentnom zahtjevu 4, naznačen time, da je u obliku mekane želatinske kapsule koja sadrži 50 mg djelatne tvari, ekvivalenta slobodne baze, odabrane od sljedećih sastava A, B i C:
[image]
6. Farmaceutski oblik za doziranje prema patentnom zahtjevu 4, naznačen time, da je u obliku mekane želatinske kapsule koja sadrži 75 mg djelatne tvari, ekvivalenta slobodne baze, odabrane od sljedećih sastava A, B i C:
[image]
7. Farmaceutski oblik za doziranje prema patentnom zahtjevu 4, naznačen time, da je u obliku mekane želatinske kapsule koja sadrži 100 mg djelatne tvari, ekvivalenta slobodne baze, odabrane od sljedećih sastava A, B i C:
[image]
8. Farmaceutski oblik za doziranje prema patentnom zahtjevu 4, naznačen time, da je u obliku mekane želatinske kapsule koja sadrži 125 mg djelatne tvari, ekvivalenta slobodne baze, odabrane od sljedećih sastava A, B i C:
[image]
9. Farmaceutski oblik za doziranje prema patentnom zahtjevu 4, naznačen time, da je u obliku mekane želatinske kapsule koja sadrži 150 mg djelatne tvari, ekvivalenta slobodne baze, odabrane od sljedećih sastava A, B i C:
[image]
10. Farmaceutski oblik za doziranje prema patentnom zahtjevu 4, naznačen time, da je u obliku mekane želatinske kapsule koja sadrži 200 mg djelatne tvari, ekvivalenta slobodne baze, odabrane od sljedećih sastava A, B i C:
[image]
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157750 | 2008-06-06 | ||
| PCT/EP2009/056895 WO2009147220A1 (en) | 2008-06-06 | 2009-06-04 | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| EP09757601.1A EP2313087B2 (en) | 2008-06-06 | 2009-06-04 | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20190181T1 HRP20190181T1 (hr) | 2019-03-22 |
| HRP20190181T4 true HRP20190181T4 (hr) | 2024-07-05 |
Family
ID=41017080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190181TT HRP20190181T4 (hr) | 2008-06-06 | 2009-06-04 | Farmaceutski dozni oblik za trenutno oslobađanje jednog derivata indolinona |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20110190318A1 (hr) |
| EP (1) | EP2313087B2 (hr) |
| JP (2) | JP5583119B2 (hr) |
| KR (1) | KR20110022586A (hr) |
| CN (1) | CN102056599A (hr) |
| AR (1) | AR072060A1 (hr) |
| AU (1) | AU2009254556B2 (hr) |
| BR (1) | BRPI0913235A2 (hr) |
| CA (1) | CA2726648A1 (hr) |
| CL (1) | CL2010001362A1 (hr) |
| CO (1) | CO6280468A2 (hr) |
| CY (1) | CY1121272T1 (hr) |
| DK (1) | DK2313087T4 (hr) |
| EA (1) | EA201001857A1 (hr) |
| EC (1) | ECSP10010717A (hr) |
| ES (1) | ES2711913T5 (hr) |
| FI (1) | FI2313087T4 (hr) |
| HR (1) | HRP20190181T4 (hr) |
| HU (1) | HUE042524T2 (hr) |
| IL (1) | IL209055A0 (hr) |
| LT (1) | LT2313087T (hr) |
| MA (1) | MA32386B1 (hr) |
| MX (1) | MX338001B (hr) |
| PE (1) | PE20100050A1 (hr) |
| PL (1) | PL2313087T5 (hr) |
| PT (1) | PT2313087T (hr) |
| RS (1) | RS58280B2 (hr) |
| SG (1) | SG191607A1 (hr) |
| SI (1) | SI2313087T2 (hr) |
| TR (1) | TR201901579T4 (hr) |
| TW (1) | TW201002692A (hr) |
| UA (1) | UA107560C2 (hr) |
| UY (1) | UY31876A (hr) |
| WO (1) | WO2009147220A1 (hr) |
| ZA (1) | ZA201007972B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077604A1 (en) * | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
| PT2299987T (pt) | 2008-06-06 | 2018-05-21 | Boehringer Ingelheim Int | Forma de dosagem farmacêutica em cápsula compreendendo uma formulação de suspensão de um derivado de indolinona |
| CA2883807A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
| TWI642768B (zh) | 2013-06-04 | 2018-12-01 | 蒙諾蘇爾有限公司 | 水溶性膜之密封溶液、相關方法及相關物品 |
| US20150044288A1 (en) | 2013-07-31 | 2015-02-12 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| US20200069679A1 (en) | 2016-12-12 | 2020-03-05 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol |
| CN110573161A (zh) * | 2017-03-28 | 2019-12-13 | 勃林格殷格翰国际有限公司 | 用于治疗肌营养不良的方法的尼达尼布 |
| WO2019081235A1 (en) | 2017-10-23 | 2019-05-02 | Boehringer Ingelheim International Gmbh | NEW ASSOCIATION OF ACTIVE AGENTS FOR THE TREATMENT OF PROGRESSIVE FIBROSANT INTERSTITIAL PNEUMOPATHY (PF-ILD) |
| PL3761980T3 (pl) | 2018-03-07 | 2024-06-10 | Pliant Therapeutics, Inc. | Związki aminokwasowe i sposoby zastosowania |
| US20230135671A1 (en) | 2020-04-01 | 2023-05-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
| EP4098246A1 (en) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation of nintedanib |
| WO2024037982A1 (en) | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3579384D1 (de) | 1984-07-24 | 1990-10-04 | Scherer Gmbh R P | Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung. |
| DE19603402A1 (de) | 1995-02-24 | 1996-08-29 | Basf Ag | Weichgelatinekapseln |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| DK1948180T3 (da) * | 2005-11-11 | 2013-05-27 | Boehringer Ingelheim Int | Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer |
| PT2299987T (pt) * | 2008-06-06 | 2018-05-21 | Boehringer Ingelheim Int | Forma de dosagem farmacêutica em cápsula compreendendo uma formulação de suspensão de um derivado de indolinona |
| ME02273B (me) * | 2008-06-06 | 2016-02-20 | Boehringer Ingelheim Int | Farmaceutska kombinacija |
| EP2387401A1 (en) * | 2009-01-14 | 2011-11-23 | Boehringer Ingelheim International GmbH | Method for treating colorectal cancer |
| US8802384B2 (en) * | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| JP2012526766A (ja) * | 2009-05-14 | 2012-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍性及び線維性疾患の処置における新規な併用療法 |
-
2009
- 2009-04-06 UA UAA201100096A patent/UA107560C2/ru unknown
- 2009-06-04 SG SG2013040332A patent/SG191607A1/en unknown
- 2009-06-04 DK DK09757601.1T patent/DK2313087T4/da active
- 2009-06-04 EA EA201001857A patent/EA201001857A1/ru unknown
- 2009-06-04 TR TR2019/01579T patent/TR201901579T4/tr unknown
- 2009-06-04 ES ES09757601T patent/ES2711913T5/es active Active
- 2009-06-04 WO PCT/EP2009/056895 patent/WO2009147220A1/en active Application Filing
- 2009-06-04 MX MX2010013092A patent/MX338001B/es active IP Right Grant
- 2009-06-04 EP EP09757601.1A patent/EP2313087B2/en active Active
- 2009-06-04 CA CA2726648A patent/CA2726648A1/en not_active Abandoned
- 2009-06-04 HR HRP20190181TT patent/HRP20190181T4/hr unknown
- 2009-06-04 HU HUE09757601A patent/HUE042524T2/hu unknown
- 2009-06-04 SI SI200931930T patent/SI2313087T2/sl unknown
- 2009-06-04 AU AU2009254556A patent/AU2009254556B2/en active Active
- 2009-06-04 BR BRPI0913235A patent/BRPI0913235A2/pt not_active IP Right Cessation
- 2009-06-04 PL PL09757601.1T patent/PL2313087T5/pl unknown
- 2009-06-04 FI FIEP09757601.1T patent/FI2313087T4/fi active
- 2009-06-04 PT PT09757601T patent/PT2313087T/pt unknown
- 2009-06-04 RS RS20190128A patent/RS58280B2/sr unknown
- 2009-06-04 US US12/995,893 patent/US20110190318A1/en not_active Abandoned
- 2009-06-04 CN CN200980121070XA patent/CN102056599A/zh active Pending
- 2009-06-04 PE PE2009000780A patent/PE20100050A1/es not_active Application Discontinuation
- 2009-06-04 LT LTEP09757601.1T patent/LT2313087T/lt unknown
- 2009-06-04 KR KR1020107027313A patent/KR20110022586A/ko not_active Application Discontinuation
- 2009-06-04 JP JP2011512134A patent/JP5583119B2/ja active Active
- 2009-06-05 AR ARP090102040A patent/AR072060A1/es unknown
- 2009-06-05 TW TW098118827A patent/TW201002692A/zh unknown
- 2009-06-08 UY UY0001031876A patent/UY31876A/es not_active Application Discontinuation
-
2010
- 2010-11-01 IL IL209055A patent/IL209055A0/en unknown
- 2010-11-08 ZA ZA2010/07972A patent/ZA201007972B/en unknown
- 2010-12-03 CO CO10152530A patent/CO6280468A2/es not_active Application Discontinuation
- 2010-12-06 CL CL2010001362A patent/CL2010001362A1/es unknown
- 2010-12-06 MA MA33403A patent/MA32386B1/fr unknown
- 2010-12-23 EC EC2010010717A patent/ECSP10010717A/es unknown
-
2013
- 2013-03-08 US US13/790,334 patent/US20130203773A1/en not_active Abandoned
-
2014
- 2014-02-10 US US14/176,478 patent/US20140163040A1/en not_active Abandoned
- 2014-02-28 JP JP2014039871A patent/JP5992937B2/ja active Active
-
2019
- 2019-02-19 CY CY20191100212T patent/CY1121272T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190181T4 (hr) | Farmaceutski dozni oblik za trenutno oslobađanje jednog derivata indolinona | |
| SI2299987T1 (en) | A capsule pharmaceutical dosage form, comprising a suspension formulation of an indolinone derivative | |
| TW592731B (en) | A method for the production of a hard capsule | |
| Efentakis et al. | Design and evaluation of a dry coated drug delivery system with an impermeable cup, swellable top layer and pulsatile release | |
| Lee et al. | Axial displacements in external and internal implant‐abutment connection | |
| JP6389237B2 (ja) | 非ゼラチン性腸溶性軟質カプセル | |
| WO2006000228B1 (en) | Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention | |
| Ugurel et al. | Mechanical resistance of screwless morse taper and screw‐retained implant‐abutment connections | |
| JP2008504257A5 (hr) | ||
| WO2008093848A1 (ja) | ホスファチジルコリンを含有する炎症マーカー低減組成物 | |
| Alhnan et al. | Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability | |
| HRP20230299T3 (hr) | Farmaceutski pripravci koji sadrže visoko hlapljive silikone | |
| Bakshi et al. | Recent trends in hard gelatin capsule delivery system | |
| BR112020003255A2 (pt) | comprimidos com alto teor de ingrediente ativo de sais de aminoácido graxo ômega-3 | |
| DK1880718T3 (da) | Farmaceutisk præparat til oral administration med kontrolleret frigivelse af aktivt stof i tyndtarmen og fremgangsmåde til fremstilling deraf | |
| CN114072138A (zh) | 延迟释放软凝胶胶囊 | |
| MX2009012782A (es) | Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados. | |
| ES2602571T3 (es) | Elemento de sellado en banda para cápsulas duras que presentan PEG encapsulado en las mismas | |
| HRP20221366T1 (hr) | Postupci poboljšanja i/ili stabilizacije srčane funkcije kod bolesnika s fabrijevom bolešću | |
| BR112020018255A2 (pt) | Cápsulas softgel entéricas | |
| TW202233165A (zh) | 緩釋軟膠囊 | |
| TW202233164A (zh) | 緩釋軟膠囊 | |
| Zeno et al. | The effect of tissue entrapment on screw loosening at the implant/abutment interface of external‐and internal‐connection implants: an in vitro study | |
| Drašković et al. | Comprehensive evaluation of formulation factors affecting critical quality attributes of casted orally disintegrating films | |
| KR20240037990A (ko) | 소프트겔 캡슐 |